A novel combination therapy involving enzalutamide and talazoparib has demonstrated a statistically significant improvement in overall survival rates for patients with late-stage prostate cancer. The findings, stemming from the ongoing TALAPRO-2 trial, offer a promising new treatment avenue for metastatic castration-resistant prostate cancer.
The global TALAPRO-2 trial, spearheaded by Neeraj Agarwal, MD, FASCO, at Huntsman Cancer Institute, evaluated the efficacy of combining enzalutamide (XTANDI) with talazoparib (TALZENNA). Enzalutamide, a hormone treatment, is a standard therapy for metastatic castration-resistant prostate cancer. Talazoparib, a PARP inhibitor, prevents damaged cancer cells from repairing themselves.
Clinical Impact and Significance
"Metastatic prostate cancer is the second most common cause of cancer-related death in men. Having a novel combination of well-tolerated medications significantly improving overall survival rates is terrific news for our patients," said Dr. Agarwal. The combination therapy aims to provide more effective treatment options for patients with advanced prostate cancer.
The FDA approved the novel treatment in 2023. Earlier results from the TALAPRO-2 trial indicated that the combination therapy reduced the risk of cancer progression by 55% compared to enzalutamide alone. The latest data further corroborate the efficacy of the combination in extending overall survival.
Background on Prostate Cancer
Prostate cancer is the second most common cancer among men, with approximately one in forty-four men dying from the disease, according to the American Cancer Society. This new treatment provides hope for many prostate cancer patients.
Study Sponsorship
The TALAPRO-2 trial was sponsored by Pfizer, with additional support from the National Institutes of Health/National Cancer Institute and Huntsman Cancer Foundation.
